The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer
- 1 June 2005
- journal article
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 75 (3) , 303-306
- https://doi.org/10.1016/j.radonc.2005.03.015
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- No Apparent Benefit at 5 Years From a Course of Neoadjuvant/Concurrent Androgen Deprivation for Patients With Prostate Cancer Treated With a High Total Radiation DoseJournal of Urology, 2003
- Does hormonal manipulation in conjunction with permanent interstitial brachytherapy, with or without supplemental external beam irradiation, improve the biochemical outcome for men with intermediate or high-risk prostate cancer?BJU International, 2003
- Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trialThe Lancet, 2002
- Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantationInternational Journal of Radiation Oncology*Biology*Physics, 2002
- Examining the Role of Neoadjuvant Androgen Deprivation in Patients Undergoing Prostate BrachytherapyJournal of Clinical Oncology, 2000
- The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostateInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972